AROMASIN Drug Patent Profile
✉ Email this page to a colleague
When do Aromasin patents expire, and when can generic versions of Aromasin launch?
Aromasin is a drug marketed by Pfizer and is included in one NDA.
The generic ingredient in AROMASIN is exemestane. There are fifteen drug master file entries for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the exemestane profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Aromasin
A generic version of AROMASIN was approved as exemestane by HIKMA on April 1st, 2011.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for AROMASIN?
- What are the global sales for AROMASIN?
- What is Average Wholesale Price for AROMASIN?
Summary for AROMASIN
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 2 |
| Raw Ingredient (Bulk) Api Vendors: | 102 |
| Clinical Trials: | 85 |
| Drug Prices: | Drug price information for AROMASIN |
| What excipients (inactive ingredients) are in AROMASIN? | AROMASIN excipients list |
| DailyMed Link: | AROMASIN at DailyMed |
Recent Clinical Trials for AROMASIN
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Breast Cancer Research Foundation | Phase 2 |
| NRG Oncology | Phase 2 |
| Oana Danciu | Phase 2 |
Pharmacology for AROMASIN
| Drug Class | Aromatase Inhibitor |
| Mechanism of Action | Aromatase Inhibitors |
US Patents and Regulatory Information for AROMASIN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pfizer | AROMASIN | exemestane | TABLET;ORAL | 020753-001 | Oct 21, 1999 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for AROMASIN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Pfizer | AROMASIN | exemestane | TABLET;ORAL | 020753-001 | Oct 21, 1999 | ⤷ Sign Up | ⤷ Sign Up |
| Pfizer | AROMASIN | exemestane | TABLET;ORAL | 020753-001 | Oct 21, 1999 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for AROMASIN
See the table below for patents covering AROMASIN around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Czechoslovakia | 258498 | METHOD OF ANDROSTA-1,4-DIEN-3,17-DIONES PRODUCTION | ⤷ Sign Up |
| Czech Republic | 9104135 | ⤷ Sign Up | |
| United Kingdom | 2177700 | SUBSTITUTED ANDROSTA-1,4-DIENE-3,17-DIONES AND PROCESS FOR THEIR PREPARATION | ⤷ Sign Up |
| Greece | 861780 | PROCESS FOR THE PREPARATION OF SUBSTITUTED ANDROST -1,4-DIENE-3,17-DIONES | ⤷ Sign Up |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
